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INTRODUCTION
Liver diseases are a major global health problem
affecting millions of people worldwide.1 Among the liver
diseases, cirrhosis is the most common liver disorder
caused by a variety of causes like viral hepatitis, alcohol,
autoimmune and metabolic causes.2,3 Cirrhosis is
common in Pakistan.4 In Pakistan, most common cause
of cirrhosis is hepatitis C followed by hepatitis B and
then non B non C (NBNC) related cirrhosis.5-6 NBNC
entity is not very well addressed in Pakistan which might
include the metabolic causes such as hemochromatosis.
Hereditary Hemochromatosis (HHC) is the most
common inherited disorder of iron metabolism in which
there is an inappropriate increase in intestinal iron
absorption.7 Unregulated iron traffic causes excessive
iron deposition in parenchymal cells of the liver, heart,
pancreas, and other endocrine organs, sometimes
leading to organ damage.8
Most data on HHC is from west and there is very limited
data from Pakistan. The present case record review of
the subjects with HHC was done in a tertiary care
hospital in Pakistan to review clinicopathological
manifestations and recognition of its importance in
subjects with deranged liver function tests.
METHODOLOGY
Study was done in the Section of Gastroenterology,
Department of Medicine, The Aga Khan University and
Hospital. Twenty two charts were identified as having
hemochromatosis from medical records (Health
information and management system) by using the ICD
code 9CM. These 22 HHC cases were retrospectively
analyzed for clinical presentations, liver function tests,
serum ferritin, transferrin saturation, hepatic imaging
and histology. Ethical exemption was sought because it
was chart review. All cases were diagnosed from
January 2002 to October 2012. Patient's data was
recorded on proforma.
Statistical analysis was done by using the Statistical
Package for Social Science (SPSS). Mean ±SD were
used for continuous variables and numbers and
percentages were used for categorical variables.
RESULTS
Twenty two charts were identified as having hereditary
hemochromatosis. All of them were males with a mean
age of 53 ± 9.2 years at the time of diagnosis. Two
presented before the age of 40 years. The most
common presentation in this group of patients was skin
pigmentation in 17 (77%), followed by loss of libido/
impotence in 11 (50%) and then arthralgias in 10 (45%)
and weakness in 6 (27%). Eleven (50%) had diabetes
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mellitus and only one patient had concomitant cardiac
involvement. Patients with diabetes were diagnosed
earlier as compared to those without diabetes. Eighteen
(81%) had cirrhosis at the time of diagnosis. Fifteen
(68.2%) patients had ascites and two subjects had
hemetemesis secondary to esophageal varices shown
in Table I. Among the 15 subjects with ascites, 5 had
spontaneous bacterial peritonitis. None had hepato-
cellular carcinoma. Only 3 (14%) patients had regular
phlebotomy.
The serum Iron studies are summarized in Table II.
Serum iron was 164 ± 53 ug/dl (normal range = 50 - 170
ug/dl), ferritin 3391 ± 1960 ug/L (normal ranges = 5 - 365
ug/L), TIBC 202 ± 61 ug/dl (normal range = 250 - 400
ug/L), and transferrin saturation was 76.8 ± 14% (normal
range = 15 - 55%).
Liver biopsy was done in 10 (45%) patients using per-
cutaneous route in 9 subjects while transjugular route
was used in one. Biopsy specimens were stained with
hematoxylin and eosin for routine histology, with
Masson's trichrome for collagen, and with Pearls'
Prussian blue for iron. Facility for hepatic iron concen-
tration and genetic testing is not available in study
center. Pearls' Prussian blue stain showed excessive
(grade IV) iron deposition in all biopsy specimens.
DISCUSSION
Hereditary Hemochromatosis (HHC) is the most
common inherited disorder of iron metabolism in which
there is an inappropriate increase in intestinal iron
absorption.7 Iron deposition in the liver may result in
hepatomegaly, cirrhosis, hepatocellular carcinoma and
premature death.9,10 Cardiac deposition may result in
cardiomyopathy, arrhythmias and heart failure.11 Other
manifestations are skin pigmentation, bronze diabetes,
arthralgias and impotence.12 HHC is most commonly
identified in Caucasians. It is much less common in
Hispanic, Asians and black persons.13
The present study of chart review of hemochromatosis
cases seen over a period of 10 years showed a male
predominance, iron overload on biopsy and advanced
liver disease. This is the largest case series from
Pakistan on HHC in which most of these patients
presented with advanced liver disease. The mean age at
onset was slightly higher in this cohort compared to
other comparison studies in which HHC is detected
earlier (Table II). The reason of late presentation may be
because of lack of awareness of disease itself by the
patients or local physicians (Internists) whom they
approach initially with early, non-specific symptoms and
signs rather than advanced disease.8 It is prerequisite to
exclude secondary forms of iron overload, such as those
caused by repeated red blood cell transfusions or
anemia owing to ineffective erythropoiesis. Although all
lead to raised serum iron parameters, they are treated
differently.14 It has generally been acknowledged that
women present with symptomatic HHC about 10 years
later in life than men, presumably because of
physiological iron loss from menstruation and
pregnancy. Preponderance of males in the present study
could be due to men having more access to health
facilities in Pakistan. Symptoms and signs of HHC are
initially non-specific, so the disease is often diagnosed at
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Table I: Clinical characteristics, signs and symptoms at identification.
Age (mean±SD) 53 ± 9.2
Male 22 (100%)
Skin pigmentation 17 (77%)







UGI bleed 2 (9.1%)
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Table II: Comparison of HHC with different countries.
Pakistan Iran27 Ireland28 USA29
Year 2013 2012 2004 1997
Study period 2002 - 2012 2006 - 2010 2004 1990 - 1995
Place of study Karachi, Pakistan Tehran, Iran Dublin, Ireland Missouri, USA
Number of cases 22 12 209 40
Male (%) 100 92 51 65
Mean age at onset 53 ± 9.2 39 ± 12.6 42 (14 - 79) 46 ± 2
How patients were identified Symptomatic index cases Symptomatic index cases Family screening Family screening
Symptoms / signs
Skin pigmentation 17 (77%) 9 (75%) 17 (8.1%) 2 (5%)
Loss of libido / impotence 11 (50%) 5 (41.7%) NA 3 (12%) male
Arthralgias 10 (45%) 8 (66.7%) 15 (7.2%) 5 (13%)
Weakness / fatigue 6 (27%) NA 77 (36.8%) 10 (25%)
Diabetes 11 (50%) 7 (58.3%) 3 (1.4%) 2 (5%)
Cirrhosis 18 (81%) 6 (50%) 9 (5%) 3 (7.5%)
Serum iron studies
Ferritin (ug/L) 3391 ± 1960 2642 ± 1257 809 M, 283F 1,025 ± 155
Transferrin saturation (%) 76.8 ± 14 79 ± 18.8 ≥ 52 84 ± 3
a late stage when substantial organ damage has already
occurred.15 HHC burden was higher in male population
from Iran and USA but same in both the gender from
Ireland. With a greater proportion of patients identified
on screening, the age of diagnosis for women and men
has equalized.13,16 The most common mode of
presentation in present cohort was darker skin and loss
of libido/impotence which is consistent with the study
from Iran.  However, in the studies from Ireland and
USA, majority of the patients (upto 73%) were
asymptomatic or had nonspecific symptoms. Eighteen
(81%) patients had already developed cirrhosis at the
time of presentation in this cohort as compared to Irish
and American studies. In the studies from Ireland and
USA, most patients were identified earlier because of
family screening. Thus, as more patients with HHC are
identified by screening, they are more likely to be
asymptomatic and without significant disease. Early
diagnosis and treatment of HHC can prevent end-stage
complications of cirrhosis, diabetes and hepatocellular
cancer.17 Patients with HHC can have a normal life
expectancy if treatment is started before cirrhosis
occurs.18 In this cohort of patients, higher ferritin level
was seen as compared to the study from Iran, USA and
Ireland due to late presentation when majority
developed the decompensated liver disease.19-22
Diagnostic strategies for HHC are serum iron markers
including serum ferritin levels and transferrin saturation,
liver histology and genetic testing for HFE mutations.23
The diagnostic markers in this study showed high serum
ferritin and transferrin saturations. The results are
comparable with the other three studies as shown in
(Table II).
HHC should be suspected in patients who have
unexplained deranged liver function tests and diabetes
mellitus or positive family history for liver disease. A
clinician should check for at least serum ferritin and
transferrin saturation in case of unexplained abnormal
LFTs to rule out HHC. HHC is inherited in an autosomal
recessive disease, with variable penetrance.24 A
homozygous mutation in the hereditary
hemochromatosis gene, HFE is responsible for HHC.14
HFE gene was identified on chromosome 6 in 1996. Two
major mutations responsible for HFE-related HHC are
C282Y and H63D.25 Discovery of the genetic defect has
allowed for early detection through screening of family
members of known cases.19 We have found this major
limitation in this study that none of the patients had
genetic analysis for HFE mutation.
CONCLUSION
Hemochromatosis is not a rare disease in this part of
world and should be looked in those subjects whose
liver function tests are deranged especially when viral
serology is negative. HHC can easily be detected early
in patients with deranged liver functions by doing the
serum iron studies and, therefore, prevent the later
development of chronic liver disease. All physicians
should further evaluate patients with abnormal iron
studies on screening chemistry panels.
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